Ferro intravenoso em crianças e adolescentes com doença inflamatória intestinal

• Ano de defesa: 2018
• Autor(a) principal: Venturieri, Maissara Obara [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Iron deficiency anemia; Intravenous iron; Crohn's disease; Ulcerative colitis; Child; Adolescent; Anemia ferropriva; Ferro intravenoso; Doença de Crohn; Colite ulcerativa; Criança; Adolescente
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6641845; https://repositorio.unifesp.br/handle/11600/52449

Objective: To evaluate the therapeutic response and the adverses effects of Noripurum EV® in children and adolescents with inflammatory bowel disease and iron deficiency anemia. Methods: A cohort study was conducted at the Pediatric Gastroenterology Clinic of the Federal University of São Paulo (UNIFESP) from January 2013 to May 2018, on patients with Crohn's disease (CD) and ulcerative colitis (UC) who received treatment for iron deficiency anemia with Noripurum EV®. The research was approved by institutional review board nº: 0951/2016. Data were analyzed by SigmaPlot 14.0 and Bioestat 5.3 (α5%). Results: Noripurum EV® was applied in 13 patients and 3 required reinfusion after 12 years; summing up to 16 cases. Of the 16 subjects, 10 (62.5%) were male. The mean (SD) age was 11.3 (4.6) years, 75% (12/16) with CD and 25% (4/16) with UC. Iron deficiency anemia was found in 93.7% patients and iron deficiency anemia associated with anemia of chronic disease in 6.3%. All patients presented a hemoglobin increase (p <0.001), whose mean (SD) was 2.8 (1.3) g / dl, after median (2575 percentiles) of 4.5 (3.06.0) weeks at the end of intravenous iron infusion. No adverse events have been reported, even in patients receiving IV iron after application of adalimumab. Conclusions: Noripurum EV® in pediatric patients with inflammatory bowel disease and iron deficiency anemia was effective and safe. Therefore, Noripurum EV® can be considered as an adequate option for clinical management of in these individuals.